The latest on the coronavirus pandemic and vaccines

By Sarah Faidell, Brad Lendon, Joshua Berlinger, Mary Ilyushina and Ed Upright, CNN

Updated 8:38 a.m. ET, February 19, 2021
35 Posts
Sort byDropdown arrow
4:46 p.m. ET, February 18, 2021

Pfizer-BioNTech will start additional vaccine studies in children as young as 5 soon

From CNN’s Amanda Sealy

Pfizer-BioNTech said they are expecting to start Covid-19 vaccine studies in children aged five to 11 in the next couple of months, according to a company news release.

The companies said they also have plans to study the vaccine in children younger than five later this year.

Pfizer-BioNTech’s current trial – for children aged 12 to 15 – began enrolling participants in October of last year. That trial is now fully enrolled and the companies say “the relevant data are planned to be submitted to the regulatory authorities in the second quarter of 2021.”

Currently, Pfizer’s Covid-19 vaccine has been granted emergency use authorization by the US Food and Drug Administration for those who are aged 16 and above. There is currently no FDA authorized Covid-19 vaccine for children. 

3:10 p.m. ET, February 18, 2021

Nevada detects state’s first case of Covid-19 variant first identified in South Africa

From CNN’s Artemis Moshtaghian

Health officials in Nevada detected the state’s first known case of the B.1.351 coronavirus variant, first identified in South Africa, in a sample collected in Reno, according to a statement from the University of Nevada, Reno School of Medicine (UNR Med). 

The Nevada State Public Health Laboratory (NSPHL) located at UNR Med said it first sequenced the specimen on Saturday, and through further analysis of data detected the B.1.351 strain and confirmed it on Wednesday.

The sample came from a person who had traveled from South Africa and became symptomatic after arriving in Reno.

Some more context: The NSPHL has been analyzing positive Covid-19 virus samples for variants since mid-December 2020 through whole genome sequencing, the statement reads.

"Daily sequencing of positive cases is not necessarily the norm,” NSPHL Director Mark Pandori said, adding that, “daily genetic testing will allow us to find cases closer to the time that they arrive, possibly limiting community spread. In this case, the carrier was a traveler from South Africa. So hopefully this is an example of that benefit."  

On Tuesday, the US Centers for Disease Control and Prevention reported that 19 cases of the B.1.351 variant have been identified in 10 states. This doesn’t represent the total number of such cases circulating in the US, but just those that have been found by analyzing positive samples.

 

3:26 p.m. ET, February 18, 2021

About 57.7 million Covid-19 vaccine doses administered in the US

From CNN’s Deidre McPhillips

Carolyn Fowler of the Los Angeles Unified School District receives a Covid-19 vaccine on Wednesday.
Carolyn Fowler of the Los Angeles Unified School District receives a Covid-19 vaccine on Wednesday. Frederic J. Brown/AFP/Getty Images

About 57.7 million doses of Covid-19 vaccine have been administered in the United States, according to data published Thursday by the US Centers for Disease Control and Prevention.

The CDC reported that 57,737,767 total doses have been administered, about 79% of the 73,377,450 doses distributed.

That’s nearly 1.5 million more administered doses reported since yesterday. The seven-day average of doses administered has been ticking down slightly since Tuesday, from about 1.7 million doses per day to about 1.6 million.

More than 41 million people have now received at least one dose of the vaccine and more than 16 million people have been fully vaccinated, CDC data shows. 

Data published by the CDC may be delayed, and doses may not have been given on the day reported.

3:41 p.m. ET, February 18, 2021

Participants in global Pfizer-BioNTech vaccine trial for pregnant women receive their first doses

From CNN’s Amanda Sealy

A pharmacy technician prepares doses of the Pfizer-BioNTech vaccine on January 30.
A pharmacy technician prepares doses of the Pfizer-BioNTech vaccine on January 30. Michael Ciaglo/Getty Images

Pfizer-BioNTech announced Thursday that the first participants of its global Covid-19 vaccine trial for pregnant women have received their first doses.

The Phase 2/3 trial will enroll about 4,000 healthy pregnant women age 18 or older, according to a news release from the company. They will be vaccinated during 24 to 34 weeks of gestation and receive two doses of the vaccine or placebo 21 days apart.

The first doses were administered to US participants. The trial will be conducted in nine countries: the United States, Canada, Argentina, Brazil, Chile, Mozambique, South Africa, UK and Spain.

“We are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations,” Dr. William Gruber, Pfizer’s senior vice president of vaccine clinical research and development, said in the release.

The company said the trial is designed to evaluate the vaccine in pregnant women, but also their infants, who will be monitored until they’re about six months old, for safety and for the transfer of potentially protective antibodies. Once an infant is born, Pfizer-BioNTech said trial participants will be unblinded and adults in the placebo group will receive the vaccine.

Currently, the US Centers for Disease Control and Prevention says pregnant people are at increased risk for severe illness from Covid-19, and there’s limited data about the safety of the vaccines for pregnant people. It suggests pregnant patients talk with their doctor to make the decision about whether to be vaccinated against Covid-19.

2:47 p.m. ET, February 18, 2021

Food and packaging highly unlikely to spread Covid-19, US agencies say in reminder

From CNN's Lauren Mascarenhas

Food and food packaging are highly unlikely to spread Covid-19, the US Food and Drug Administration, US Department of Agriculture and the Centers for Disease Control and Prevention said in a reminder Thursday.

“Consumers should be reassured that we continue to believe, based on our understanding of currently available reliable scientific information, and supported by overwhelming international scientific consensus, that the foods they eat and food packaging they touch are highly unlikely to spread SARS-CoV-2,” the FDA wrote in a statement.

The three agencies said they wanted to stress the lack of credible evidence to suggest that food or its packaging are associated with transmission of the virus.

Covid-19 is a respiratory illness spread from person to person, unlike foodborne viruses that can make people sick through contaminated food, the FDA said.

“Given that the number of virus particles that could be theoretically picked up by touching a surface would be very small and the amount needed for infection via oral inhalation would be very high, the chances of infection by touching the surface of food packaging or eating food is considered to be extremely low,” it added.

“Considering the more than 100 million cases of COVID-19, we have not seen epidemiological evidence of food or food packaging as the source of SARS-CoV-2 transmission to humans.”

Chinese officials have repeatedly raised the possibility the virus is spread by packaged frozen foods, but the CDC and World Health Organization have both said this is highly unlikely.

 

2:38 p.m. ET, February 18, 2021

Fauci says minor things can set back vaccine production by months

From CNN's Lauren Mascarenhas

Dr. Anthony Fauci joins President Joe Biden while touring the National Institutes of Health on February 11.
Dr. Anthony Fauci joins President Joe Biden while touring the National Institutes of Health on February 11. Oliver Contreras/Sipa/Bloomberg/Getty Images

Even seemingly minor things can set back vaccine production by months, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said talking about the Johnson & Johnson vaccine supply mix up.                                                       

The US had been expecting between 20 to 30 million Johnson & Johnson vaccine doses by April, but now expects fewer than 20 million by that time. An administration official told CNN on Tuesday that the change was due to a miscommunication. The administration now expects single digit millions of doses to initially be available, if the vaccine is authorized for emergency use.

“The issue is, we would have hoped that we would have gotten more vaccines at the time that they get their emergency use authorization,” Fauci said in an MSNBC interview Thursday.

“It's a really complicated situation, when you're dealing with the production of biologics. Things – minor things – seemingly minor can set you back by weeks or a month or so,” he added. 

Johnson & Johnson is on track to meet its promise of producing 100 million vaccine doses for the US by July, Fauci said.

“We would have hoped that we would have had a lot of vaccines available, but we don't,” he said. “We're going to probably have single digits vaccine available right away, a bit more the next month, and then after that, it'll really scale up so that they will almost certainly meet their contractual arrangement.”

Johnson & Johnson has asked the Federal Drug Administration to authorize its vaccine for emergency use and an independent review of the vaccine is scheduled for Feb. 26. 

1:50 p.m. ET, February 18, 2021

Workers use PPE if employers give it to them, CDC study finds

From CNN's Naomi Thomas

US workers will use personal protective equipment if their employers give it out, a new study finds.

Researchers from the CDC’s National Institute for Occupational Safety and Health looked at survey answers from 742 non-healthcare, non-remote workers last June who didn’t use PPE at work before the Covid-19 pandemic. 

Just 29% used PPE if it was left entirely up to them, the team reported Thursday in the US Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly. More than half of those who used PPE were required to do so by employers. And use doubled if the PPE was provided, they found.

About 30% of workers who were not required to use PPE were provided the equipment by employers, the NIOSH team found, and 45% of those workers used the PPE. That compared to 22% of workers who didn’t use PPE if it wasn’t provided.

The team also found 8% of workers were forbidden to use PPE by their employers. “Overall, lower-income workers were more likely than were higher-income workers to be prohibited from using hazard controls or to be unable to obtain them,” the team wrote.

The team also noted why wearing PPE matters.

“Failure to protect workers from COVID-19 might exacerbate existing health disparities, including those among lower-income populations,” the team said. “Workers with lower incomes are more likely than are those with higher incomes to have preexisting health conditions that might increase the risk for severe COVID-19–associated illness.”

Among those who did not use PPE and other hazard controls in the workplace, 15% were unable to obtain them and 77%  said they thought that they weren’t necessary.

Lower-income workers were more likely to be prohibited from use or unable to obtain them, compared with higher-income workers.

“Employers can help protect workers against Covid-19 by requiring and encouraging occupational hazard control use and providing recommended hazard controls, along with other Covid-19 workplace precautions,” said the report.

 

1:00 p.m. ET, February 18, 2021

European Commission has "a lot to learn" from vaccine rollout, says Denmark's foreign minister

From CNN’s Samantha Tapfumaneyi

Jeppe Kofod, Denmark’s foreign minister, spoke to CNN's Becky Anderson on Thursday.
Jeppe Kofod, Denmark’s foreign minister, spoke to CNN's Becky Anderson on Thursday.

The European Commission has a “lot to learn” from its Covid-19 vaccine rollout, Denmark’s Foreign Minister Jeppe Kofod told CNN’s Becky Anderson in an interview on Thursday.

“I think there's a lot to learn from the process that also the European Union has to learn, the Commission that has been responsible for negotiating contracts on behalf of member states and the whole setup around the pandemic,” Kofod said.

Asked about the criticism the EU has faced on its vaccine rollout, Kofod said:

“I think we all are desperate to get the vaccine. Now we are ready. In the case of Denmark, we can vaccinate 100,000 people a day if we have the vaccine arrive into the country.”

Kofod agreed that the rollout “has not been a full success.”

The foreign minister pointed out that it’s not a shortage of vaccines that has been a problem but the delay in arrivals.

“We are all desperate to get our population vaccinated sooner than later,” Kofod said.

12:52 p.m. ET, February 18, 2021

More than 1.8 million vaccine doses have been administered in Pennsylvania so far

From CNN's Kristina Sgueglia

Eugene Proctor receives a Covid-19 vaccine at the Pittsburgh VA Medical Center.
Eugene Proctor receives a Covid-19 vaccine at the Pittsburgh VA Medical Center. Jeff Swensen/Getty Images

Pennsylvania has administered more than 1.8 million vaccine doses so far, and expects 326,850 doses to have been allocated through Feb. 20.

According to the state's health department, 85% of those, or 1,365,523 doses that were administered, were first doses, and 40% or 467,115 doses were second doses.

Vaccination numbers do not include Philadelphia, which is its own jurisdiction, or federal facilities, which are working directly with the federal government, the department said.

The state reports 3,345 additional cases and 84 deaths.

Note: These numbers were released by the state health department and may not line up with Johns Hopkins University's Covid-19 numbers.